Company Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia.
The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease.
The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
| Country | Australia |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. David A. Stamler M.D. |
Contact Details
Address: Level 3, 460 Bourke Street Melbourne, C3 VIC 3000 Australia | |
| Phone | 61 3 9349 4906 |
| Website | alteritytherapeutics.com |
Stock Details
| Ticker Symbol | ATHE |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001131343 |
| CUSIP Number | 02155X106 |
| ISIN Number | US02155X2053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David A. Stamler M.D. | Chief Executive Officer |
| Geoffrey Paul Kempler B.Sc. | Co-Founder and Non-Executive Chairman |
| Phillip Allen Hains BBus(Acc), C.A., M.B.A. | Chief Financial Officer and Company Secretary |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of Research and Development Advisory Board |
| Dr. Steven D. Targum | Chief Medical Advisor |
| Dr. Robert Cherny | Head of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 6-K | Report of foreign issuer |
| Jun 13, 2024 | 6-K | Report of foreign issuer |
| May 31, 2024 | 6-K | Report of foreign issuer |
| May 23, 2024 | 6-K | Report of foreign issuer |
| May 9, 2024 | 6-K | Report of foreign issuer |
| Apr 30, 2024 | 6-K | Report of foreign issuer |
| Apr 29, 2024 | 6-K | Report of foreign issuer |
| Apr 29, 2024 | 6-K | Report of foreign issuer |
| Apr 17, 2024 | 6-K | Report of foreign issuer |
| Apr 15, 2024 | 6-K | Report of foreign issuer |